Mega Lifesciences Public Company Limited - Asset Resilience Ratio
Mega Lifesciences Public Company Limited (MEGA-R) has an Asset Resilience Ratio of 2.45% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Mega Lifesciences Public Company Limited carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Mega Lifesciences Public Company Limited's Asset Resilience Ratio has changed over time. See shareholders equity of Mega Lifesciences Public Company Limited for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mega Lifesciences Public Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MEGA-R market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 0% |
| Short-term Investments | ฿350.06 Million | 2.45% |
| Total Liquid Assets | ฿350.06 Million | 2.45% |
Asset Resilience Insights
- Limited Liquidity: Mega Lifesciences Public Company Limited maintains only 2.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mega Lifesciences Public Company Limited Industry Peers by Asset Resilience Ratio
Compare Mega Lifesciences Public Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Mega Lifesciences Public Company Limited (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Mega Lifesciences Public Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.47% | ฿350.30 Million ≈ $10.92 Million |
฿14.21 Billion ≈ $442.92 Million |
+0.02pp |
| 2023-12-31 | 2.45% | ฿355.52 Million ≈ $11.08 Million |
฿14.52 Billion ≈ $452.56 Million |
+0.16pp |
| 2022-12-31 | 2.29% | ฿335.41 Million ≈ $10.45 Million |
฿14.65 Billion ≈ $456.52 Million |
-0.22pp |
| 2021-12-31 | 2.51% | ฿333.66 Million ≈ $10.40 Million |
฿13.27 Billion ≈ $413.67 Million |
+0.69pp |
| 2020-12-31 | 1.82% | ฿211.09 Million ≈ $6.58 Million |
฿11.59 Billion ≈ $361.24 Million |
-0.15pp |
| 2019-12-31 | 1.97% | ฿207.14 Million ≈ $6.46 Million |
฿10.53 Billion ≈ $328.30 Million |
-1.85pp |
| 2018-12-31 | 3.81% | ฿367.33 Million ≈ $11.45 Million |
฿9.63 Billion ≈ $300.24 Million |
-4.18pp |
| 2017-12-31 | 7.99% | ฿696.75 Million ≈ $21.72 Million |
฿8.72 Billion ≈ $271.79 Million |
-0.22pp |
| 2016-12-31 | 8.21% | ฿651.66 Million ≈ $20.31 Million |
฿7.94 Billion ≈ $247.51 Million |
-4.29pp |
| 2015-12-31 | 12.49% | ฿951.11 Million ≈ $29.65 Million |
฿7.61 Billion ≈ $237.28 Million |
+6.04pp |
| 2014-12-31 | 6.45% | ฿433.83 Million ≈ $13.52 Million |
฿6.72 Billion ≈ $209.53 Million |
+6.12pp |
| 2013-12-31 | 0.33% | ฿21.49 Million ≈ $669.89K |
฿6.54 Billion ≈ $203.72 Million |
+0.20pp |
| 2012-12-31 | 0.12% | ฿5.17 Million ≈ $161.08K |
฿4.14 Billion ≈ $128.89 Million |
-- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more